Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...
CRSwNP, for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is estimated that about 107 million people in China suffer from chronic sinusitis ...
Hosted on MSN18d
Depemokimab reviewed for asthma and CRSwNP in AsiaSimilarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo. Depemokimab, a monoclonal antibody targeting ...
Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback